Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130523 | 0.94 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2NUDT1 | |
| SCHEMBL19689304 | 0.94 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2NUDT1 | |
| SCHEMBL13596143 | 0.93 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2NUDT1 | |
| SCHEMBL4127225 | 0.89 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL29235511 | 0.88 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL4132970 | 0.88 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2NR1H2 | |
| SCHEMBL4420189 | 0.88 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL15016366 | 0.87 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2NR1H2 | |
| SCHEMBL4130620 | 0.87 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL29583645 | 0.86 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-12599672-B2 | KRAS proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4635958-A1 | PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-10-22 | — | — | EP | disclosed |
| EP-4631942-A1 | PAN-KRAS DEGRADING AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| US-20250144225-A1 | KRAS Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2025-05-08 | — | — | US | disclosed |
| EP-4536356-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Xenon Pharmaceuticals Inc. (CA) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025076044-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024217515-A1 | HETEROCYCLIC RING-SUBSTITUTED AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海复宏汉霖生物技术股份有限公司 | 2024-10-24 | — | — | WO | disclosed |
| WO-2024125642-A1 | PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| CN-110088108-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-06-14 | — | — | CN | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-1358198-A4 | NOVEL ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES, SALTS THEREOF AND PROCESS FOR THE PREPARATION OF THE SAME | LG LIFE SCIENCES LTD (KR) | 2008-03-05 | — | — | EP | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2006-12-28 | — | — | US | disclosed |
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | LG LIFE SCIENCES LTD. (KR) | 2006-03-09 | — | — | US | disclosed |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2004-04-01 | — | — | US | disclosed |
| EP-1358198-A1 | NOVEL ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES, SALTS THEREOF AND PROCESS FOR THE PREPARATION OF THE SAME | LG Chem Investment, Ltd. (KR) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057288-A1 | NOVEL ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES, SALTS THEREOF AND PROCESS FOR THE PREPARATION OF THE SAME | LG LIFE SCIENCES LTD. (KR) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599672-B2 | KRAS proteolysis targeting chimeras | KRAS, HRAS, NRAS | SMYD2 2026/4885CYP3A4 4429/4885HTT 2128/4885 |
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | PNP, TYMP, ENTPD5 | SMYD2 3736/4885CYP3A4 1213/4885HTT 4713/4885 |
| US-20250144225-A1 | KRAS Proteolysis Targeting Chimeras | KRAS, HRAS, NRAS | SMYD2 2415/4885CYP3A4 4433/4885HTT 559/4885 |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | SMYD2 3859/4885CYP3A4 456/4885HTT 3597/4885 |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | SMYD2 3859/4885CYP3A4 456/4885HTT 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.